Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine ... long drought at the FDA for new-mechanism antidepressants. ICER’s final report ...

It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of ... Johnson's Spravato (esketamine), which was approved ...

Esketamine (Spravato ... but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades. The approval of concizumab-mtci (Alhemo) injection marks a ...

Two cutting edge treatments for though-to-treat major depression are remarkably successful: TMS Therapy and Spravato (Esketamine ... necessary tools and coping mechanisms required to manage ...

The good news is there are now more than 20 medications with different mechanisms of action ... include cognitive behavior therapy or “talk therapy,” as well as esketamine—an N-methyl-D-aspartate ...